Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.

Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
复制标题

DOI:
10.1371/journal.pone.0128288
复制
发表时间:
2015
期刊:
影响因子:
3.7
通讯作者:
Tanigaki K
Tanigaki K
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Yoshimura Y;Shiino A;Muraki K;Fukami T;Yamada S;Satow T;Fukuda M;Saiki M;Hojo M;Miyamoto S;Onishi N;Saya H;Inubushi T;Nozaki K;Tanigaki K

文献摘要

参考文献

被引文献

相似文献

多形性胶质母细胞瘤(GBM)由于浸润性生长和复发而与高死亡率相关。患者的中位生存期不足 15 个月,这增加了对新疗法的需求。我们发现三氧化二砷和 Myc 抑制剂 10058F4 均可诱导 GBM 的癌症干样细胞 (CSC) 分化,并且三氧化二砷显着增强 10058F4 的抗增殖作用,但不增强凋亡作用。 EGFR 驱动的基因工程 GBM 小鼠模型表明,这种协同效应在表达 EGFRvIII 的 INK4a/Arf-/- 神经干细胞 (NSC) 中比对照野生型 NSC 更高。此外,用三氧化二砷和10058F4处理GBM CSC异种移植物导致肿瘤生长显着减少,分化增加,同时体内原神经和间充质GBM CSC减少。我们的研究首次评估了三氧化二砷和 10058F4 在 GBM CSC 分化中的相互作用,并评估了三氧化二砷和 10058F4 组合作为未来 GBM 分化治疗有前途的方法的新机会。
Glioblastoma multiforme (GBM) is associated with high mortality due to infiltrative growth and recurrence. Median survival of the patients is less than 15 months, increasing requirements for new therapies. We found that both arsenic trioxide and 10058F4, an inhibitor of Myc, induced differentiation of cancer stem-like cells (CSC) of GBM and that arsenic trioxide drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects. EGFR-driven genetically engineered GBM mouse model showed that this cooperative effect is higher in EGFRvIII-expressing INK4a/Arf-/- neural stem cells (NSCs) than in control wild type NSCs. In addition, treatment of GBM CSC xenografts with arsenic trioxide and 10058F4 resulted in significant decrease in tumor growth and increased differentiation with concomitant decrease of proneural and mesenchymal GBM CSCs in vivo. Our study was the first to evaluate arsenic trioxide and 10058F4 interaction in GBM CSC differentiation and to assess new opportunities for arsenic trioxide and 10058F4 combination as a promising approach for future differentiation therapy of GBM.
DOI: 10.1016/j.cmet.2013.04.013
发表时间: 2013-06-04
期刊: Cell metabolism
影响因子: 29
作者:
Babic I;Anderson ES;Tanaka K;Guo D;Masui K;Li B;Zhu S;Gu Y;Villa GR;Akhavan D;Nathanson D;Gini B;Mareninov S;Li R;Camacho CE;Kurdistani SK;Eskin A;Nelson SF;Yong WH;Cavenee WK;Cloughesy TF;Christofk HR;Black DL;Mischel PS
通讯作者: Mischel PS
DOI: 10.1172/jci62129
发表时间: 2012-09-01
影响因子: 15.9
作者:
Carracedo, Arkaitz;Weiss, Dror;Pandolfi, Pier P.
通讯作者: Pandolfi, Pier P.
DOI: 10.1038/sj.onc.1210128
发表时间: 2007-05-17
期刊: ONCOGENE
影响因子: 8
作者:
Buschbeck, M.;Uribesalgo, I.;Di Croce, L.
通讯作者: Di Croce, L.
DOI: 10.1016/j.cmet.2011.06.011
发表时间: 2011-08-03
期刊: Cell metabolism
影响因子: 29
作者:
Folmes CD;Nelson TJ;Martinez-Fernandez A;Arrell DK;Lindor JZ;Dzeja PP;Ikeda Y;Perez-Terzic C;Terzic A
通讯作者: Terzic A
DOI: 10.1158/0008-5472.can-13-3703
发表时间: 2014-08-15
期刊: Cancer research
影响因子: 11.2
作者:
Chen G;Kong J;Tucker-Burden C;Anand M;Rong Y;Rahman F;Moreno CS;Van Meir EG;Hadjipanayis CG;Brat DJ
通讯作者: Brat DJ